Cytokinetics

Cytokinetics

Biotechnology
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

$10.3B

Market Cap • 9/11/2026

1997

(29 years)

Founded

2004

(22 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

P/S

152,7

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

EPS

Market Cap

Market Cap

10,3B

EV

10,4B

EV/Revenue

154,2

EV/EBITDA

-15

EV/EBIT

-14,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-13,9%

Total Yield

-13,9%

Payout

0%

Retained Earnings

-3,9B

Profitability

Gross Margin

88%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

586,6%

Capex/Revenue

37,3%

Capex/D&A

201,3%

Capex/OCF

-4,5%

SBC/OCF

% PPE

7,9%

% Goodwill

0%

ROE

329,8%

ROIC

Growth

CAGR Revenue 5Y

3,2%

CAGR Op. Income 5Y

41,1%

CAGR Net Income 5Y

41,8%

CAGR EPS 5Y

26,9%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

6,7

Quick Ratio

6,6

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium